Cargando…
ERCC1 Overexpression Increases Radioresistance in Colorectal Cancer Cells
SIMPLE SUMMARY: The 20–30% of locally advanced rectal cancer patients undergoing preoperative concurrent chemoradiotherapy had no expected efficacy, and ERCC1 overexpression was found in these tumor tissue patients. In the interest of confirming and adding details to our understanding of that correl...
Autores principales: | Huang, Yi-Jung, Huang, Ming-Yii, Cheng, Tian-Lu, Kuo, Shih-Hsun, Ke, Chien-Chih, Chen, Yi-Ting, Hsieh, Yuan-Chin, Wang, Jaw-Yuan, Cheng, Chiu-Min, Chuang, Chih-Hung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563575/ https://www.ncbi.nlm.nih.gov/pubmed/36230725 http://dx.doi.org/10.3390/cancers14194798 |
Ejemplares similares
-
XPF–ERCC1 Blocker Improves the Therapeutic Efficacy of 5-FU- and Oxaliplatin-Based Chemoradiotherapy in Colorectal Cancer
por: Huang, Ming-Yii, et al.
Publicado: (2023) -
Polymorphisms in XPD and ERCC1 Associated with Colorectal Cancer Outcome
por: Huang, Ming-Yii, et al.
Publicado: (2013) -
ERCC overexpression associated with a poor response of cT4b colorectal cancer with FOLFOX-based neoadjuvant concurrent chemoradiation
por: Huang, Ming-Yii, et al.
Publicado: (2020) -
Five-year survival outcomes of intensity-modulated radiotherapy with simultaneous integrated boost (IMRT-SIB) using forward IMRT or Tomotherapy for breast cancer
por: Lee, Hsin-Hua, et al.
Publicado: (2020) -
HIF-1α Expression Increases Preoperative Concurrent Chemoradiotherapy Resistance in Hyperglycemic Rectal Cancer
por: Huang, Yi-Jung, et al.
Publicado: (2022)